All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

*Clostridium difficile* is the most common cause of hospital-acquired infections \[[@pone.0124483.ref001]\]. Recent studies report the prevalence of *Clostridium difficile* infection (CDI) among hospitalized patients to be 0.9% \[[@pone.0124483.ref002]\]. Studies have reported an increase in hospitalization rates associated with *C*. *difficile* infection (CDI) \[[@pone.0124483.ref003]\]. There has also been a remarkable increase in mortality among CDI patients in hospitals \[[@pone.0124483.ref004]\], as mortality from CDI increased five-fold from 1999/2000-2005/2006 \[[@pone.0124483.ref005]\] and CDI accounts for≥ \$4.8 billion in excess health-care costs \[[@pone.0124483.ref006]\].

Solid organ transplant (SOT) recipients are at high risk for CDI because of impaired defense mechanisms resulting from immunosuppression, perioperative antibiotic use and organ failure \[[@pone.0124483.ref007]--[@pone.0124483.ref009]\]. A study among 49,198 SOT recipients that used data from the 2009 US inpatient sample database noted that these patients are at greater risk for CDI compared to the general hospital population and estimated the prevalence of infection in SOT patients to be 2.7% \[[@pone.0124483.ref010]\]. However, this earlier study captured CDI episodes that occurred in an indeterminate time after transplantation and did not provide data for the initial hospitalization period post-transplantation where the most CDI episodes are expected to occur. In order to address these issues, we performed a meta-analysis to estimate the prevalence of CDI in SOT patients during the peri-transplant and post-transplantation period in university-based, tertiary medical centers. Also, we aimed to stratify the results based on type of the organ transplanted and estimate the recurrence rate and severity of CDI in this specific patient population.

Materials and Methods {#sec002}
=====================

Study Selection {#sec003}
---------------

We (S.P and I.M.Z) searched PubMed (1978 to February 2015), EMBASE and Google Scholar databases to identify studies that reported the prevalence of CDI among SOT recipients. The concise search term for PubMed was transplant\* AND (clostrid\* OR difficile OR diarrhea OR infect\* OR (clostridium difficile) OR (pseudomembranous colitis)). The terms infect\* and diarrhea were included in the search term in order to retrieve all articles that report episodes of CDI along with other infections, as well as episodes of CDI along with other causes of diarrhea in SOT patients. Articles that were considered eligible by title and abstract reading were assessed in full text. The reference lists of the eligible studies were also reviewed to find possible studies that match our search. Our meta-analysis follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines ([S1 Table](#pone.0124483.s008){ref-type="supplementary-material"}) \[[@pone.0124483.ref011]\].

Inclusion Criteria {#sec004}
------------------

Only studies that reported the prevalence of CDI among SOT patients during the peri-transplant period were included. Peri-transplant period was defined as "the time of transplant to the first discharge from the hospital" \[[@pone.0124483.ref012]\]. Studies that did not include follow-up of patients during the initial hospitalization post transplantation were excluded. Studies with adequate quality as described below in the *Quality Assessment* section were included. Also, studies published in a language other than English were excluded from the analysis.

Outcomes of Interest {#sec005}
--------------------

The primary outcome of interest of this meta-analysis was the prevalence of CDI among SOT patients. CDI was defined as "the presence of symptoms (usually diarrhea) and either a stool test result positive for *C*. *difficile* toxins or toxigenic *C*. *difficile* or colonoscopic findings demonstrating pseudomembranous colitis" \[[@pone.0124483.ref013]\]. Prevalence was calculated as the proportion of the patients diagnosed with CDI among the patients "at risk", i.e. patients who received solid organ transplantation. A subgroup analysis was performed according to the type of organ transplanted, location of study conduction, and size of study population.

Data Extraction {#sec006}
---------------

Studies that were considered for inclusion in the meta- analysis were evaluated by two reviewers (S.P. and I.M.Z.) and all relevant information from the text, figures, tables and charts were extracted for analysis. Studies that contained duplicate information were included only once. Extracted data include period of the study, patient population and location. The total number of patients who underwent SOT during the study period and total number of CDI cases among them were also extracted. The median follow-up duration, methods of *C*. *difficile* isolation, study design, number of severe cases, and number of recurrent episodes were also included. Recurrent CDI episodes were defined as onset of symptoms after complete abatement of symptoms with proper antibiotic therapy with additional positive CDI assays. Only data about the first CDI recurrence were used for the estimation of the recurrent rate in our study population. Severe cases were represented by cases that needed surgery for colitis and/or cases that required admission in the intensive care unit due to complications directly related to CDI and/or died from CDI-related cause \[[@pone.0124483.ref010]\].

Quality Assessment {#sec007}
------------------

The methodological quality of eligible studies was assessed by two reviewers (S.P. and I.M.Z.) using the Newcastle-Ottawa Quality Assessment Scale, which is a 'star based' rating system \[[@pone.0124483.ref014]\]. The parameters used to evaluate the quality of individual studies were representativeness of the exposed cohort, ascertainment of exposure, demonstration that outcome of interest was not present at start of the study, assessment of outcome, follow-up long enough for outcomes to occur and adequacy of follow up of cohorts \[[@pone.0124483.ref015]\]. Two parameters 'selection of the non-exposed cohort' and 'comparability of cohorts on the basis of the design or analysis' were not applicable to our analysis, so each article could get up to 6 stars. We considered the study population representative of the exposed cohort if data on CDI were provided for all available transplant patients and not among a specific sub population. The outcome was assessed by the cases who presented with symptoms and laboratory diagnosis of CDI. Follow-up duration of at least 3 months was considered adequate for the outcome to occur in the cohort. Studies that received 5 stars were considered of adequate quality for extraction of relevant information.

Statistical Analysis {#sec008}
--------------------

We performed the meta-analysis using a random-effects model to estimate the pooled prevalence and the 95% confidence intervals (CI), using Der-Simonian and Laird weights \[[@pone.0124483.ref016]\]. The double arcsine methodology was used to avoid an undue large weight for studies with low or high prevalence (prevalence close to 0 or 1) \[[@pone.0124483.ref017]\]. The Egger's test \[[@pone.0124483.ref018],[@pone.0124483.ref019]\] was used to assess small study effects. Between-study variance τ^2^estimation \[[@pone.0124483.ref020]\] was used to assess statistical heterogeneity. Subgroup analyses were used to account for possible sources of heterogeneity. The meta and metareg commands of the Stata v13 software package (Stata Corporation, College Station, TX) were used to perform the statistical analysis. The statistical significance threshold was set at 0.05.

Results {#sec009}
=======

Our literature search yielded 75,940 citations and the last day of the literature search was February 9, 2015. After scrutinizing the titles and abstracts of retrieved articles, 162 articles were accessed in full text. Among these 162 articles, 127 studies were excluded because they did not contain extractable data on prevalence of CDI among SOT patients. Of the total 35 remaining eligible studies, 10 contained partially overlapping data \[[@pone.0124483.ref021]--[@pone.0124483.ref030]\] and data were extracted with an effort to extract the maximum available data. We included 30 studies in the final analysis coded from 35 articles. The details of the selection process of eligible articles are presented in the Flow chart ([Fig 1](#pone.0124483.g001){ref-type="fig"}).

![Flow chart of meta-analysis.](pone.0124483.g001){#pone.0124483.g001}

The studies included in our analysis were published from 1991--2014 and reported data on 21,683 patients. We stratified the patients according to the type of organ transplanted. Among them 10,659 (49.2%) were kidney recipients, 5,433 (25.1%) liver, 1,556 (7.2%) lung, 1,397 (6.4%) heart, 539 (2.5%) pancreas, 60 (0.27%) intestine, 2 (0.01%) hand, 751 (3.5%) multiple-organs and 1508 (7%) were unspecified solid organ transplant recipients. Among the multiple-organ transplant recipients; combined kidney/pancreas transplant was by far the most common combination (n = 729, 97.1%). Data from individual studies are presented in [Table 1](#pone.0124483.t001){ref-type="table"} and all studies were considered of adequate quality on the basis of Newcastle-Ottawa scale ([S2 Table](#pone.0124483.s009){ref-type="supplementary-material"}).

10.1371/journal.pone.0124483.t001

###### Individual Studies.

![](pone.0124483.t001){#pone.0124483.t001g}

  Author                                          Year   Origin                                                     Population                                                                               Study Period                                        N (Transplant recipients)                                                   n- CDI                                                    Recurrence (No. of cases)        Severity (No. of cases)                          Quality score
  ----------------------------------------------- ------ ---------------------------------------------------------- ---------------------------------------------------------------------------------------- --------------------------------------------------- --------------------------------------------------------------------------- --------------------------------------------------------- -------------------------------- ------------------------------------------------ ---------------
  Mittal C\[[@pone.0124483.ref038]\]              2014   Henry Ford Hospital, Detroit, Michigan, U.S.A              Liver transplant patients                                                                Jan 2000- Dec 2010                                  Li: 970                                                                     Li: 183                                                   31                               Colectomy:5                                      6
  Hsu JL\[[@pone.0124483.ref031]\]                2014   University of Wisconsin, U.S.A                             Kidney or Liver transplant patients                                                      Jan 1994- Dec 2008                                  4666 (K:3630, Li:1036)                                                      170 (K:107, Li:63)                                        29                               ICU admission: 11 Colectomy:0                    5
  Tsapepas DS\[[@pone.0124483.ref027]\]           2014   Columbia University Medical Center                         Single Solid organ transplant patients                                                   Sep 2009- Dec 2012 (Median follow-up:23 months)     Li:331, Lu: 200, H:254                                                      Li: 9, Lu: 14, H:5                                        4                                ICU admission/ Colectomy: NR Mortality:1         6
  Garg S\[[@pone.0124483.ref054]\]                2014   Johns Hopkins University, U.S.A                            Liver transplant patients                                                                Jan 2006-Jun 2013                                   Li: 251                                                                     Li: 32                                                    9                                NR                                               5
  Dorschner P\[[@pone.0124483.ref055]\]           2014   Northwestern university Feinberg SoM, Chicago              Solid organ transplant patients                                                          Jan 2012- Jul 2012 (Follow-up: 30 days)             146                                                                         1                                                         NR                               NR                                               5
  Neofytos D\[[@pone.0124483.ref043]\]            2013   Johns Hopkins Hospital, U.S.A                              Adult Kidney transplant patients                                                         Jan 2008-Dec 2010                                   K:603                                                                       K: 37                                                     4                                Colectomy/ ICU admission: 1                      5
  Deshpande A\[[@pone.0124483.ref030]\]           2013   Cleveland Clinic, Ohio, U.S.A                              Single Organ transplant patients                                                         Jan 2003- Dec 2009                                  Lu: 525, Li: 809                                                            Lu: 37, Li: 69                                            Discrete data on episodes only   Colectomy:2 Mortality: 0                         6
  Wheeler M\[[@pone.0124483.ref056]\]             2013   University of North Carolina                               Solid organ transplant patients                                                          2005--2012 (Follow-up: 1 year)                      872                                                                         31                                                        5                                Colectomy: 0 Mortality: 0                        6
  Kittleson M\[[@pone.0124483.ref057]\]           2013   Sinai Heart Institute, CA, U.S.A                           Adult Heart transplant patients                                                          2000--2010 (Median follow-up: 1year)                H: 554                                                                      H:22                                                      NR                               NR                                               5
  Lee JT\[[@pone.0124483.ref025]\]                2013   University of Minnesota, U.S.A                             Lung transplant patients                                                                 Jan 2000-Mar 2011                                   Lu: 388                                                                     Lu:89                                                     36                               Total severe cases: 5 (Colectomy:3 Mortality:2   6
  Shah SA \[[@pone.0124483.ref028]\]              2013   Columbia University, Weill Cornell Medical Center, U.S.A   Adult Kidney or Pancreas transplant recipients                                           Jan 2009- Feb 2011 (Median follow-up: 291 days)     998 (K: 942, P: 56)                                                         28 (K:24, P:4)                                            8                                NR                                               6
  Boutros M \[[@pone.0124483.ref051]\]            2012   McGill University Health Center, Montreal, Canada          Single or Multi-Organ transplant patients                                                Jan 1999- Mar 2010                                  1331(K: 814, Li: 430, H: 112, P:109, K+P: 88, K+H:10, K+Li:7)               165 (K:92, Li: 90, H: 9, K+P:8)                           14                               Colectomy:6 ICU admission: 26 Mortality: 14      5
  Ott E \[[@pone.0124483.ref058]\]                2011   Europe                                                     Cardio-thoracic transplant patients                                                      2007--2009                                          366                                                                         21                                                        NR                               Colectomy: 0                                     5
  Abid S \[[@pone.0124483.ref050]\]               2011   University College of Medicine, U.S.A                      Kidney or Liver transplant patients                                                      2005--2009                                          K: 365, Li: 41                                                              K:41, Li:6                                                NR                               NR                                               6
  Mitu- Pretorian OM \[[@pone.0124483.ref045]\]   2011   Manchester Royal Infirmary UK                              Kidney and/or Pancreas transplant patients                                               Jan 2004- Dec 2007 (Follow up: 1 year)              682 (K:576, P:18, K+P: 88)                                                  24 (K+P: 4, K: 20, P:0)                                   NR                               Colectomy: 2                                     6
  Rosen JB \[[@pone.0124483.ref052]\]             2010   Texas Children Hospital, U.S.A                             Pediatric lung transplant patients                                                       Oct 2002--2008                                      Lu:74                                                                       Lu: 4                                                     2                                Ileostomy: 1                                     5
  Rostambeigi N \[[@pone.0124483.ref059]\]        2010   Mayo Clinic College of Rochester, MN, USA                  Adult Pancreas and/or Kidney transplant patients                                         Jan 1998- July 2006 (Median follow-up: 6.4 years)   216 (K+P: 149, P: 67)                                                       9 (K+P:6, P:3)                                            1                                NR                                               5
  Coltart IC \[[@pone.0124483.ref053]\]           2009   King's College Hospital, UK                                Liver transplant patients                                                                Jan 2006- April 2007                                Li: 191                                                                     Li: 31                                                    NR                               Colectomy: 0 Death: 0                            5
  Gunderson CC\[[@pone.0124483.ref046]\]          2008   Oschner Medical Center, Louisiana, USA                     Lung transplant patients                                                                 Nov 1990- Nov 2005 (Median follow-up: 2.7 years)    Lu: 202                                                                     Lu:15                                                     NR                               Colectomy:2                                      6
  Theunissen C\[[@pone.0124483.ref047]\]          2008   Erasame University Hospital, Belgium                       Adult lung transplant patients with Cystic Fibrosis                                      Jan 1998- Dec 2004 (Median follow-up: 4.6 years)    Lu: 49                                                                      Lu: 16                                                    NR                               Severe cases: 5 (Surgery:2,Mortality:2           6
  Stelzmueller I \[[@pone.0124483.ref021]\]       2007   Innsbruck Medical University, Austria                      Single and Multi-organ transplant patients                                               Jan 1994-Dec 2005                                   2799 (K:1438, Li:651, P:289, H:242, Lu:118, H+Lu:5, I:27,Islet:25,Hand:2)   36 (K:4, L:20, P:2, H:3, Lu:4, H+Lu:5, Intes:2, Hand:1)   NR                               Colectomy: 2                                     5
  Munoz P \[[@pone.0124483.ref032]\]              2007   University of Madrid, Spain                                Heart transplant patients                                                                Jan 1993- Dec 2005                                  H: 235                                                                      H: 35                                                     10                               Colectomy: 0                                     6
  Hashimoto M \[[@pone.0124483.ref060]\]          2007   Tokyo University Hospital, Japan                           Adult Liver transplant patients                                                          Jan 1996-Nov 2004                                   Li: 242                                                                     Li: 11                                                    2                                NR                                               5
  Albright JB \[[@pone.0124483.ref061]\]          2007   Mayo Clinic, Jacksonville, Florida U.S.A                   Liver transplant patients (cadaveric grafts)                                             Mar 1998-Dec 2001                                   Li: 402                                                                     Li: 32                                                    7                                Colectomy:0                                      6
  Michalak G \[[@pone.0124483.ref062]\]           2005   University of Warsaw, Poland                               Patients with Diabetes and end stage renal disease with Kidney and Pancreas transplant   1998--2004                                          K+P:51                                                                      K+P:8                                                     NR                               NR                                               6
  Ziring D \[[@pone.0124483.ref063]\]             2005   David Geffen School of Medicine at UCLA, CA, U.S.A         Intestine transplant patients                                                            Nov 1991-May 2003 (Median follow-up: 12 months)     I:33                                                                        I:2                                                       NR                               NR                                               6
  Keven K \[[@pone.0124483.ref048]\]              2004   University of Pittsburgh Medical Center, U.S.A             Adult Kidney and/or Pancreas transplant patients                                         Jan 1999-Dec 2002                                   702 (K: 600, K+P: 102)                                                      35 (K: 27, K+P: 8)                                        8 (K:7, K+P:1)                   Colectomy:2 (1 death among them)                 6
  Loinaz C \[[@pone.0124483.ref064]\]             2003   University of Miami, School of Medicine, Florida, U.S.A    Adult and Pediatric Intestine, Liver/Intestine or Multi visceral transplant patients     1994--2001                                          124                                                                         3                                                         NR                               NR                                               6
  West M\[[@pone.0124483.ref049]\]                1999   University of Minnesota, U.S.A                             Adult and Pediatric Kidney and/or Pancreas transplant patients                           Jan 1985-Dec 1994                                   1932 (Pediatric K:267; Adult K:1424, K+P: 251)                              159 (Pediatric K: 43, Adult K:50, K+P:39)                 6                                No severe cases                                  6
  George DL\[[@pone.0124483.ref065]\]             1991   University of Chicago, U.S.A                               Patients receiving orthotropic Liver transplant                                          Feb 1985- July 1987 (Median follow-up: 324 days)    Li: 79                                                                      Li: 2                                                     NR                               NR                                               6

**Footnotes**: H: Heart, I: Intestine, ICU: Intensive Care Unit, K: Kidney, Li: Liver, Lu: Lungs, NR: Not reported, P: Pancreas.

Geographical location varied among the included articles. Among the 30 studies, 22 were conducted in the North America, 7 in Europe, and 1 in Asia. All studies were retrospective. Twenty one studies reported the method of isolation of *C*. *difficile*. One or more than 1 method of isolation such as stool culture and toxin detection were used in the studies. *C*. *difficile* toxin was identified using one or more of the following methods: enzyme immunoassay, radio immunoassay, tissue culture assay and PCR. The method of *C*. *difficile* isolation used in each individual study is included in [Table 2](#pone.0124483.t002){ref-type="table"}.

10.1371/journal.pone.0124483.t002

###### Individual Studies.

![](pone.0124483.t002){#pone.0124483.t002g}

  Author              Year   Follow-up                                     Recurrence (No. of cases)    Recurrence (definition)                                                                                                                                     Method of diagnosis                                                                                      Time of CDI diagnosis
  ------------------- ------ --------------------------------------------- ---------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------
  Mittal C            2014   NR                                            31                           New onset of diarrhea or positive stool toxin assay within 12 weeks of CDI                                                                                  Until2008: EIA for toxin A/B, From 2009: Glutamate dehydrogenase followed by EIA and molecular testing   Mean: 51 days
  Hsu JL              2014   NR                                            29                           Episodes of CDI\<8 weeks after resolution of symptoms from previous episode                                                                                 Positive CD culture and stool toxin, pseudomembranous colitis on endoscopy/ histopathology               Mean: 653 days
  Tsapepas DS         2014   Median follow-up: 23 months (16--31 months)   4                            Resurgence of diarrhea after the cessation of initial therapy, confirmed by a subsequent stool specimen with detection of *C*. *difficile* toxin B by PCR   Toxin detection by PCR                                                                                   51 days
  Garg S              2014   NR                                            9                            More than 1 episode of CDI in an OLT recipient at any time after OLT                                                                                        Cytotoxin assay or PCR for toxin gene B                                                                  NR
  Dorschner P         2014   30 days                                       NR                           NR                                                                                                                                                          NR                                                                                                       NR
  Neofytos D          2013   6 months                                      4                            New episode of CDI after at least14 completed days of treatment for primary CDI                                                                             Cytotoxin assay for toxins A and B or PCR                                                                Mean: 9 days
  Deshpande A         2013   NR                                            Data on recurrent episodes   CDI diagnosed using the same criteria as for the first episode and occurring after an initial CDI episode has resolved completely with treatment            Toxin detection by EIA                                                                                   Median:116 days (Lung transplant patients),23 days (Liver transplant patients)
  Wheeler M           2013   1 year                                        5                            Reappearance of CDI within 2 months                                                                                                                         Not Specified                                                                                            26 days
  Kittleson M         2013   1 year                                        1                            NR                                                                                                                                                          NR                                                                                                       NR
  Lee JT              2013   Median follow-up: 4.2 years                   36                           Recurrence of symptoms with positive CDI assay after complete abatement of symptoms with antibiotics                                                        Until 2007: Stool culture and toxin assay with EIA, From 2007: Toxin assay and PCR                       177 days (4days-6.9 years)
  Shah SA             2013   Median follow-up: 291 days                    8                            Recurrence of symptoms with positive CD PCR between 6--50 days after stopping treatment                                                                     Gene B PCR                                                                                               Median: 57 days
  Boutros M           2012   NR                                            14                           Two clinical episodes of CDI(with positive cytotoxin assay) more than two months apart                                                                      Cell culture cytotoxin assay for toxin B                                                                 NR
  Ott E               2011   NR                                            NR                           NR                                                                                                                                                          NR                                                                                                       NR
  Abid S              2011   NR                                            NR                           NR                                                                                                                                                          NR                                                                                                       NR
  Mitu-Pretorian OM   2011   NR                                            NR                           NR                                                                                                                                                          Stool culture and toxin assay                                                                            12.5 days (3days-90 days)
  Rosen B             2010   NR                                            2                            NR                                                                                                                                                          Toxin assay and PCR                                                                                      NR
  Rostambeigi N       2010   6.4 years                                     1                            NR                                                                                                                                                          NR                                                                                                       NR
  Coltart IC          2009   90 days                                       NR                           NR                                                                                                                                                          Stool toxin assay                                                                                        15.5 days
  Gunderson CC        2008   2.7 years                                     NR                           NR                                                                                                                                                          CD toxin A assay                                                                                         NR
  Theunissen C        2008   4.6 years                                     NR                           NR                                                                                                                                                          Stool culture, Detection of cytotoxin by tissue culture                                                  NR
  Stelzmueller I      2007   NR                                            NR                           NR                                                                                                                                                          Until 1995:Stool culture and toxin assay with RIA; From 1996: Stool culture and toxin assay with EIA     NR
  Munoz P             2007   50 days                                       10                           NR                                                                                                                                                          Stool culture and CD toxin B by cell culture cytotoxin test                                              Mean: 32 days
  Hashimoto M         2007   3 months                                      2                            NR                                                                                                                                                          Stool culture, ICA for CD toxin A, latex test for CD protein glutamate dehydrogenase                     Mean: 19 days
  Albright JB         2007   5 days-1999 days                              7                            NR                                                                                                                                                          EIA for toxin A and B                                                                                    NR
  Michalak G          2005   NR                                            NR                           NR                                                                                                                                                          NR                                                                                                       NR
  Ziring D            2005   12 months (2 months-69 months)                NR                           NR                                                                                                                                                          CD toxin Immunoassay                                                                                     NR
  Keven K             2004   NR                                            8                            NR                                                                                                                                                          CD toxin assay                                                                                           30 days
  Loinaz C            2003   535±58.12 days                                NR                           NR                                                                                                                                                          NR                                                                                                       NR
  West M              1999   NR                                            6                            NR                                                                                                                                                          Stool culture or CD toxin assay                                                                          NR
  George DL           1991   324 days (70 days- 883 days)                  NR                           NR                                                                                                                                                          NR                                                                                                       NR

**Footnotes:** CD: *Clostridium difficile*, CDI: *Clostridium difficile* infection, EIA: enzyme immunoassay, ICA: immune chromatographicassay, NR: not reported, PCR: polymerase chain reaction, RIA: radio immunoassay

The pooled prevalence of CDI among 21,683 SOT recipients was 7.4% \[95%CI, (5.6--9.5%), τ^2^ = 0.039\] ([Fig 2](#pone.0124483.g002){ref-type="fig"}). According to the Egger's test, we found no evidence of small study effects for the overall estimated prevalence (bias: 1.93, p-value: 0.06). We also stratified our data based on the type of organ transplanted. The prevalence of CDI inpatients who underwent transplantation for more than one organ was 12.7% \[95%CI, (6.4%-20.9%), τ^2^ = 0.069\] ([S1 Fig](#pone.0124483.s001){ref-type="supplementary-material"}). The prevalence among other single SOT recipients was: lung transplant recipients 10.8% \[95%CI, (5.5%-17.7%), τ^2^ = 0.064\] ([S2 Fig](#pone.0124483.s002){ref-type="supplementary-material"}), liver 9.1% \[95%CI, (5.8%-13.2%), τ^2^ = 0.048\] ([S3 Fig](#pone.0124483.s003){ref-type="supplementary-material"}), intestine 8% \[95% CI, (2.6%-15.9%), τ^2^ = 0.00\] ([S4 Fig](#pone.0124483.s004){ref-type="supplementary-material"}), heart 5.2% \[95%CI, (1.8%-10.2%), τ^2^ = 0.042\] ([S5 Fig](#pone.0124483.s005){ref-type="supplementary-material"}), kidney 4.7% \[95% CI, (2.6%-7.3%), τ^2^ = 0.028\] ([S6 Fig](#pone.0124483.s006){ref-type="supplementary-material"}) and pancreas 3.2% \[95% CI, (0.5%-7.9%), τ^2^ = 0.030\] ([S7 Fig](#pone.0124483.s007){ref-type="supplementary-material"}). The differences in prevalence between kidney and liver (p-value: 0.07) and kidney and lung (p-value: 0.07) were marginally significant. The prevalence of CDI among kidney transplant recipients was also lower than intestine, heart and multiple organ recipients, but these differences did not reach statistical significance \[kidney-heart (p-value: 0.83), kidney-intestine (p-value: 0.48) and kidney-multiple organs (p-value: 0.13)\].

![Prevalence of CDI among solid organ transplant recipients.](pone.0124483.g002){#pone.0124483.g002}

The estimated prevalence of CDI in SOT patients was 6.8% \[95% CI (5.0%-9.0%), τ^2^ = 0.032\] from studies conducted in North America and 10.5% \[(4.9%-18.0%), τ^2^ = 0.076\] from studies conducted in Europe. We also stratified the studies based on population size (\<200 versus \>200) and we did not find significant difference in the estimated prevalence of CDI in SOT recipients (p-value: 0.65) ([Table 3](#pone.0124483.t003){ref-type="table"}).

10.1371/journal.pone.0124483.t003

###### Summary Estimates.
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  CDI                       Studies (arms)   N        Combined Effect (95% CI)        τ^2^    P-value
  ------------------------- ---------------- -------- ------------------------------- ------- ---------
  **All Studies**           30 (35)          21,683   7.4% \[95%CI, (5.6--9.5%)\]     0.039   
  Kidney                    9                10,659   4.7% \[95% CI (2.6%-7.3%)\]     0.028   Ref
  Liver                     12               5,433    9.1% \[95% CI (5.8%-13.2%)\]    0.048   0.07
  Lungs                     7                1,556    10.8% \[95% CI (5.5%-17.7%)\]   0.064   0.07
  Heart                     6                1,397    5.2% \[95% CI (1.8%-10.2%)\]    0.042   0.83
  Pancreas                  4                539      3.2% \[95% CI (0.5%-7.9%)\]     0.030   0.54
  Intestine                 2                60       8.0% \[95% CI (2.6%-15.9%)\]    0.000   0.48
  Multiple Organ            7                751      12.7% \[95% CI (6.4%-20.9%)\]   0.069   0.13
  **Geographical region**                                                                     
  North America             22               15,737   6.8% \[95% CI (5.0%-9.0%)\]     0.032   
  Europe                    7                5,704    10.5% \[95% CI (4.9--18.0%)\]   0.076   
  **Populations**                                                                             
  ≥200 patients             22               20,936   7.1% \[95% CI (5.2%-9.4%)\]     0.037   Ref
  \<200 patients            8                747      8.6% \[95% CI (3.2%-16.1%)\]    0.099   0.65

Fifteen studies reported data on recurrence of CDI among 1,020 infected patients. Among them, 10 studies included the definition of recurrence. Three studies defined an episode as recurrent when the diagnosis was done within 8 weeks from the initial episode, 2 had a time frame longer than 8 weeks and the remaining 5 did not specify the duration ([Table 2](#pone.0124483.t002){ref-type="table"}). Those studies that used a longer follow-up period to define recurrent episodes tend to overestimate the rate of recurrence. The reported recurrence rate was estimated to be 19.7% \[95% CI, (13.7%-26.6%), τ^2^ = 0.073\]. Definition of recurrence, time to recurrence, mean time to diagnosis and methods of isolation of *C*. *difficile* for individual studies are presented in the [Table 2](#pone.0124483.t002){ref-type="table"}. Finally the reported prevalence of severe CDI from 19 studies was 5.3% \[95% CI (2.3%-9.3%), τ^2^ = 0.097\] and among the 1,243 *C*. *difficile* infected patients that were included in these studies there were 27 reported cases of CDI related colectomy, 37 patients had ICU admission and 20 patients died due to CDI related complications. The prevalence of colectomy due to CDI related complications in our study was 2.7% \[95% CI (1.3%-4.6%), τ^2^ = 0.023\]. Due to limited data on individual cases that required ICU admission and/or died, statistical representation could not be done in our analysis.

Discussion {#sec010}
==========

*C*. *difficile* infection has been increasingly recognized among SOT recipients \[[@pone.0124483.ref031]\]. The estimated prevalence of CDI in SOT patients in our study was 7.4%, which is higher than the 0.9% reported in the general hospital population \[[@pone.0124483.ref002]\]. In our study, lung and liver transplant patients had higher prevalence of CDI compared to kidney transplant recipients and this difference was marginally significant. There was no significant difference in the prevalence based on the size of the study population. Recurrence of CDI episodes was seen in 19.7% of cases and 5.3% of patients had severe CDI resulting in colectomy, ICU admission or death.

The overall estimated prevalence of CDI in our study is almost 3 times higher than that reported in a previous study which used data from 2009 nationwide inpatient sample database (2.7%) \[[@pone.0124483.ref010]\]. The fact that we included data from the initial hospitalization after transplantation might be the reason for the higher overall estimated prevalence. Indeed, most cases of CDI among SOT recipients are diagnosed in the early post-transplantation period due to intense immunosuppression, more frequent antimicrobial exposure and increased exposure to the health care setting \[[@pone.0124483.ref007]\]. The observed difference might also be due to the long duration of follow-up in the studies included in our meta- analysis as the follow-up time in most of our studies was up to several months and even years after transplantation.

In agreement to the study that reported the data from nationwide inpatient sample database \[[@pone.0124483.ref010]\], the prevalence of CDI was higher among lung transplant recipients in comparison to the kidney transplant patients. This might be attributed to the higher level of immunosuppression required for lung transplant patients \[[@pone.0124483.ref024]\]. Also, lung transplant patients often have a history of prolonged exposure to antibiotics and frequent hospital admissions, increasing their risk for CDI \[[@pone.0124483.ref025]\]. Also, patients who underwent transplantation of more than one organ had more than 3-times higher point prevalence of CDI than kidney recipients in our study, but this difference did not reach statistical significance, possibly due to the limited number of cases of multi-organ transplant patients.

Recurrence is a common problem in SOT patients with CDI \[[@pone.0124483.ref032]\]. Recurrent CDI can occur either because of relapse or because of re-infection; the relative frequency of each of these mechanism has not been well described \[[@pone.0124483.ref033]\]. Risk factors, such as increased length of hospital stay, prolonged use of antibiotics, immunosuppression and co-morbid conditions are associated with recurrence of CDI in SOT recipients \[[@pone.0124483.ref031],[@pone.0124483.ref034]\] and, the recurrence rate varies based on the treatment of the initial CDI episode \[[@pone.0124483.ref035]\]. The estimated recurrence rate of CDI in our study was 19.7%, and it was comparable to the median 21.6% that was recently reported in a relevant meta-analysis in the general hospital setting \[[@pone.0124483.ref036]\].

Knowledge on the outcomes of CDI in SOT recipient is remarkably limited \[[@pone.0124483.ref037]\]. Few studies have reported an increase in the in hospital mortality, a longer hospital stay and cost of health care services among this group of patients \[[@pone.0124483.ref010],[@pone.0124483.ref038]\]. CDI can also result in complications requiring colectomy and ICU admission \[[@pone.0124483.ref010]\]. Among the studies that reported data on severity, at least 5.3% of the patients had complications related to CDI in compared to 3%-5% rate of fulminant colitis in total hospitalized *C*. *difficile* infected patients \[[@pone.0124483.ref009],[@pone.0124483.ref039],[@pone.0124483.ref040]\]. The prevalence of colectomy in SOT patients due to CDI related complications in our study was 2.7% compared with 0.7% reported from the national inpatient sample database analysis in the general hospital population from 2001--2010 \[[@pone.0124483.ref041]\].

To locate possible sources of heterogeneity, we performed a subgroup analysis based on the size of the study population. Studies with small population size tend to overestimate the outcome. To evaluate this effect we stratified the studies based on population size (≥200 versus \<200). The size of study population, however, did not significantly alter the estimated prevalence of CDI in SOT recipients ([Table 3](#pone.0124483.t003){ref-type="table"}).

Notably, there were certain limitations in our study. Most of the studies that were included in our meta-analysis had a long study period (\>6 years) and did not report the prevalence of CDI stratified by year. Therefore, it was not feasible to estimate the trend over time, so it is likely that the number of CDI cases in the recent times can be even higher. The follow-up period varied widely among studies included in our analysis making a sub-analysis of the data based on follow-up duration not possible. However, out of 13 studies that reported the mean time to CDI diagnosis, only 3 had a mean time of more than 3 months with the remaining 10 studies having a mean time to diagnosis within 3 months, supporting that most of the recorded episodes of CDI occurred shortly after SOT. Detection methods used to diagnose CDI among the studies included in our analysis differ in sensitivity \[[@pone.0124483.ref042]\]. Two or more methods of isolation of *C*. *difficile* were used in most of the studies and during different time frames, but the studies did not provide stratified extractable data. Therefore, a sensitivity analysis based on the diagnostic methods used was not feasible. Also, the definition of recurrence varied between studies \[[@pone.0124483.ref024],[@pone.0124483.ref031],[@pone.0124483.ref038],[@pone.0124483.ref043]\] and in 2 of them the time to relapse of symptoms used for defining recurrent cases was longer than the 8 weeks used in current clinical practice guidelines for *Clostridium difficile* infection in adults \[[@pone.0124483.ref044]\]. The latter studies tend to overestimate the number of recurrent cases and therefore the estimated prevalence of recurrence in our study might not be a precise estimate as per the current clinical practice guidelines. The estimated recurrence rate in our study is a pooled data from studies using different treatment modalities, so different rate of treatment failure and recurrence might exist in each individual study. Twenty studies in our analysis mentioned possible risk factors associated with CDI in SOT recipients. They described prolonged exposure to antibiotics \[[@pone.0124483.ref027],[@pone.0124483.ref043],[@pone.0124483.ref045]--[@pone.0124483.ref050]\], immunosuppression \[[@pone.0124483.ref021],[@pone.0124483.ref046],[@pone.0124483.ref048]--[@pone.0124483.ref051]\] and increased days of hospitalization \[[@pone.0124483.ref026],[@pone.0124483.ref027],[@pone.0124483.ref038],[@pone.0124483.ref043],[@pone.0124483.ref045],[@pone.0124483.ref046],[@pone.0124483.ref050],[@pone.0124483.ref052],[@pone.0124483.ref053]\] to be associated with CDI. However, due to lack of raw data on each risk factor, statistical representation could not be performed in our study. Importantly, infection control measures and local epidemiology have a significant role in the prevalence of CDI among individual centers and our pooled estimation does not decrease the need of each local center to know the local prevalence.

In conclusion, our analysis estimated the pooled prevalence of CDI among SOT recipients to be almost 3 times higher than previously indicated. The observed high prevalence of CDI, along with the significant rate of severe cases, highlights the need for preventive policies, such as antimicrobial stewardship programs, strict compliance with hand hygiene and environmental decontamination that specifically target this patient population. Also, studies are needed to identify immunosuppressive and prophylactic antimicrobial regimens that are probably associated with lower risk of CDI.
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